Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
31.05.2023 - Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced the presentation of results from its Phase 1a . Seite 1
Engineered IL2-Fc Cytokine is Well-tolerated and Selectively Expands Regulatory T Cells Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies